Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1357-1363

  Varela, Juan Carlos ^a   Atkinson, Carl ^a   Woolson, Robert ^b   Keane, Thomas E ^a   Tomlinson, Stephen ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antibody; Bladder cancer; Complement; MUC1

Indexed keywords

ANTIBODY; CD59 ANTIGEN; COMPLEMENT INHIBITOR; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; MUCIN 1; MUCIN 1 ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; COMPLEMENT INHIBITION; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UPREGULATION;

ANTIBODIES; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; CA-15-3 ANTIGEN; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR ESCAPE; URINARY BLADDER NEOPLASMS;

EID: 49749121533     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23676     Document Type: Article

References (46)

1. Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 2004;108:930-6.
2. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG, Kaul A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 2000;76:176-82.
3. Simon HG, Risse B, Jost M, Oppenheimer S, Kari C, Rodeck U. Identification of differentially expressed messenger RNAs in human melanocytes and melanoma cells. Cancer Res 1996;56:3112-17.
4. Li L, Spendlove I, Morgan J, Durrant LG. CD55 is over-expressed in the tumour environment. Br J Cancer 2001;84:80-6.
5. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement-inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay accelerating factor), and CD59 (protectin). Am J Pathol 1996;149:129-42.
6. Seya T, Hara T, Matsumoto M, Sugita Y, Akedo H. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein. J Exp Med 1990;172:1673-80.
7. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93.
8. Kotera Y, Fontenot J, Pecher G, Metzger R, Finn O. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-60.
9. Petrarca C, Casalino B, von Mensdorff-Pouilly S, Rughetti A, Rahimi H, Scambia G, Hilgers J, Frati L, Nuti M. Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunol Immunother 1999;47:272-7.
10. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, van Zanten-Przybysz I, Hummel P, Nijman HW, Kenemans P, Hilgers J. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 1999;48:47-55.
11. Nakamura H, Hinoda Y, Nakagawa N, Makiguchi Y, Itoh F, Endo T, Imai K. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 1998;33:354-61.
12. Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison JG, Metcalf JS, Palesch YY, Zhang Z, Gillanders WE, Cole DJ. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001;93:162-71.
13. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-64.
14. Walsh MD, Hohn BG, Thong W, Devine PL, Gardiner RA, Samaratunga ML, McGuckin MA. Mucin expression by transitional cell carcinomas of the bladder. Br J Urol 1994;73:256-62.
15. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21.
16. Guc D, Canpinar H, Kucukaksu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur J Haematol 2000;64:3-9.
17. Hara T, Kojima A, Fukuda H, Masaoka T, Fukumori Y, Matsumoto M, Seya T. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol 1992;82:368-73.
18. Hofman P, Hsi BL, Manie S, Fenichel P, Thyss A, Rossi B. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventative mechanism of malignant tumor cells against complement attack? Breast Cancer Res Treat 1994;32:213-19.
19. Kiso T, Mizuno M, Nasu J, Shimo K, Uesu T, Yamamoto K, Okada H, Fujita T, Tsuji T. Enhanced expression of decay-accelerating factor and CD59/homologous restriction factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas. Histopathology 2002;40:339-47.
20. Koretz K, Bruderlein S, Henne C, Moller P. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 1993;68:926-31.
21. Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 2005;66:1321-6.
22. Simpson KL, Jones A, Norman S, Holmes CH. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol 1997;151:1455-67.
23. Thorsteinsson L, O'Dowd GM, Harrington PM, Johnson PM. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 1998;106:869-78.
24. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement- regulatory proteins in ovarian malignancies. Int J Cancer 1997;70:14-25.
25. Shimo K, Mizuno M, Nasu J, Hiraoka S, Makidono C, Okazaki H, Yamamoto K, Okada H, Fujita T, Shiratori Y. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma. J Gastroenterol Hepatol 2004;19:643-7.
26. Ravindranath NM, Shuler C. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:231-9.
27. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998;46:245-52.
28. Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993;53:2457-9.
29. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-83.
30. Simms MS, Hughes OD, Limb M, Price MR, Bishop MC. MUC1 mucin as a tumour marker in bladder cancer. BJU Int 1999;84:350-2.
31. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC 1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003;103:97-100.
32. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, Litvinov SV, van Kamp GJ, Meijer S, Vermorken J, Hilgers J. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 1996;32A:1325-31.
33. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999;20:576-82.
34. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634-41.
35. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 2005;65:10562-8.
36. Lutz HU. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun 2007;29:287-94.
37. Vollmers HP, Brandlein S. Natural antibodies and cancer. J Autoimmun 2007;29:295-302.
38. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol 2007;7:9-18.
39. Longhi MP, Harris CL, Morgan BP, Gallimore A. Holding T cells in check - a new role for complement regulators? Trends Immunol 2006;27:102-8.
40. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005;201:1523-30.
41. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, Song WC. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005;201:567-77.
42. Fang C, Miwa T, Shen H, Song WC. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J Immunol 2007;179:3178-86.
43. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 2007;179:5793-802.
44. Longhi MP, Sivasankar B, Omidvar N, Morgan BP, Gallimore A. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement- independent manner. J Immunol 2005;175:7098-102.
45. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003;421:388-92.
46. Ravindranath NM, Shuler C. Expression of complement restriction factors (CD46. CD55 & CD59) in head and neck squamous cell carcinomas. J Oral Pathol Med 2006;35:560-7.